Results 31 to 40 of about 604,324 (300)

Pathophysiology of elevated ascites fluid cholesterol in malignant ascites [PDF]

, 1992
The existence of marked elevations of ascitic fluid cholesterol has been observed in patients with peritoneal carcinomatosis compared to patients with cirrhosis and has been found useful in differential diagnosis.
Jüngst, Dieter, Gerbes, Alexander L., Xie, Yining   +2 more
core   +1 more source

Cholesterol delivered to macrophages by oxidized low density lipoprotein is sequestered in lysosomes and fails to efflux normally

Journal of Lipid Research, 2000
Oxidized low density lipoprotein (LDL) has been found to exhibit numerous potentially atherogenic properties, including transformation of macrophages to foam cells.
Baljinder S. Dhaliwal, Urs P. Steinbrecher   +1 more
doaj   +1 more source

Effect of a High Intake of Conjugated Linoleic Acid on Lipoprotein Levels in Healthy Human Subjects [PDF]

, 2010
Background -Trans fatty acids are produced either by industrial hydrogenation or by biohydrogenation in the rumens of cows and sheep. Industrial trans fatty acids lower high-density lipoprotein (HDL) cholesterol, raise low-density lipoprotein (LDL ...
Wanders Anne J., Siebelink, E., Brouwer, I.A.; id_orcid, Martijn B. Katan, Katan Martijn B., Martijn B Katan, Ingeborg A Brouwer, Brouwer, I.A., Els Siebelink, Anne J. W, Katan, M.B.; id_orcid, Katan, M.B., Anne J Wanders, Siebelink Els, Wanders, A.J., Ingeborg A. Brouwer, Brouwer Ingeborg A.   +16 more
core   +2 more sources

Decrease of LDL Cholesterol Through The Increase of HDL Cholesterol by Administering Garcinia mangostana L. Peel Extract in White Mice

Folia Medica Indonesiana, 2021
Highlight: • Ethanol extract of Garcinia mangostana L. peel reduce malondialdehyde. • Garcinia mangostana L. peel extract can increase non-radical products which impact in decreasing LDL cholesterol and increasing HDL cholesterol.
Hasyim As'ari
doaj   +1 more source

Cholesterol deposition in macrophages: foam cell formation mediated by cholesterol-enriched oxidized low density lipoprotein.

Journal of Lipid Research, 1997
Oxidized low density lipoprotein (LDL) is thought to mediate the transformation of macrophages to cholesterol-rich foam cells. Yet convincing evidence for this process is lacking in vitro.
P Greenspan, H Yu, F Mao, R L Gutman
doaj   +1 more source

Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method

Practical Laboratory Medicine, 2015
Objectives: It is well known that familial hypercholesterolemia (FH) is a common inherited disorder that can markedly elevate the level of plasma LDL cholesterol.
Hayato Tada, Masa-aki Kawashiri, Atsushi Nohara, Akihiro Inazu, Hiroshi Mabuchi, Masakazu Yamagishi, Kenshi Hayashi   +6 more
doaj   +1 more source

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence, Robinson, Jennifer G., Roth, Eli M., Colhoun, Helen M., Pordy, Robert, Taskinen, Marja-Riitta, Ginsberg, Henry N., Kastelein, John J. P., Baccara-Dinet, Marie T.   +8 more
core   +1 more source

Influence of an atherogenic diet on the structure of swine low density lipoproteins

Journal of Lipid Research, 1980
Five groups of three swine each were fed a basal diet supplemented with 15% tallow and either 0.0, 1.0, 1.5, 2.0%, or 2.5% cholesterol. The animals were studied over a period of 9 weeks to observe changes in plasma lipids and low density lipoproteins ...
H J Pownall, R L Jackson, R I Roth, A M Gotto, J R Patsch, F A Kummerow   +5 more
doaj   +1 more source

Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg)::Design and Rationale of the ODYSSEY OPTIONS Studies [PDF]

, 2014
The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double-blind, active-comparator, 24-week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal ...
Peter H. Jones, Robinson, Jennifer G., Hanotin, Corinne, Du, Yunling, Jones, Peter H., Harold E. Bays, Corinne Hanotin, Yunling Du, Colhoun, Helen M., Donahue, Stephen, Jennifer G. Robinson, Helen M. Colhoun, Stephen Donahue, Bays, Harold E.   +13 more
core   +1 more source

In silico and in vitro exploration of a tyrosinase for biocatalytic production of catechols

FEBS Open Bio, EarlyView.
Tyrosinase from Ralstonia pseudosolanacearum is a promising biocatalyst for producing valuable catechols from monophenol substrates. This tyrosinase is uniquely suited to this due to its high monophenolase : diphenolase ratio. We combined in silico docking and in vivo kinetic characterisation of this tyrosinase with 11 industrially relevant monophenols,
James Britton, Fang Zhao, Reeta Davis, Meg Walsh, Kevin E O'Connor, David O'Connell, Tanja Narancic   +6 more
wiley   +1 more source